Research Paper Volume 16, Issue 15 pp 11553—11567
The deubiquitinating enzymes-related signature predicts the prognosis and immunotherapy response in breast cancer
Figure 4. Value of DUBRI in predicting drug sensitivity. (A) Disparity in the reaction to typical chemotherapy drugs among individuals in the high and low DUBRI groups. (B) Variations in the responsiveness to commonly used targeted therapeutic drugs between the high and low DUBRI groups. (C, D) The association between drug sensitivity and mRNA expression of the four genes that make up PCDI was studied using the GDSC database and CTRP database.